首页 > 最新文献

Cancer Communications最新文献

英文 中文
Enhancing sensitivity of triple-negative breast cancer to DNA-damaging therapy through chemical inhibition of the m6A methyltransferase METTL3 通过化学抑制 m6A 甲基转移酶 METTL3 提高三阴性乳腺癌对 DNA 损伤疗法的敏感性
IF 16.2 1区 医学 Q1 Medicine Pub Date : 2023-12-15 DOI: 10.1002/cac2.12509
Bianca Cesaro, Alessia Iaiza, Fabio Piscopo, Marco Tarullo, Eleonora Cesari, Dante Rotili, Antonello Mai, Alberto Diana, Michela Londero, Luca Del Giacco, Riccardo Masetti, Alba Di Leone, Chiara Naro, Silvia Masciarelli, Giulia Fontemaggi, Claudio Sette, Francesco Fazi, Alessandro Fatica

Dear Editor,

N6-methyladenosine (m6A) is a critical mRNA modification catalyzed by the enzyme methyltransferase-like 3 (METTL3), with implications in RNA metabolism. METTL3 upregulation is associated with cancer progression, metastasis, and drug resistance, making it a potential therapeutic target [1]. The small-molecule METTL3 inhibitor, STM2457, has shown promise in treating acute myeloid leukemia (AML) and has demonstrated good tolerance in mice [2, 3]. However, the specific cancer types where METTL3 inhibitors are most effective remain unknown.

In breast cancer, METTL3 knockdown markedly suppresses proliferation, invasiveness, and metastasis [4]. Therefore, METTL3 inhibition is proposed as a therapeutic approach for breast cancer. Triple-negative breast cancer (TNBC), the most aggressive subtype, lacks targeted therapies, and its primary treatments involve conventional chemotherapy and DNA-damaging agents [5]. Homologous recombination deficiency, such as mutations in the breast cancer gene 1 (BRCA1) and BRCA2, serves as a predictive biomarker for identifying patients who would benefit from genotoxic chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors. Notably, METTL3 is recruited to DNA-damaged sites and is crucial for subsequent DNA repair [6, 7]. Consequently, METTL3 knockdown reduces DNA repair activity and sensitizes cancer cells to genotoxic drugs [7, 8]. However, while TNBC exhibits elevated METTL3 levels, and its nuclear catalytic activity associates with invasiveness and metastasis [9], it remains uncertain whether METTL3 inhibition enhances chemotherapy response in TNBC.

Here, we aimed to explore the potential of METTL3 catalytic inhibition by STM2457 as a valuable treatment option for TNBC. Furthermore, we assessed the impact of STM2457 on the sensitivity of TNBC cells and a TNBC patient-derived organoid line to clinical DNA-damaging therapies, like platinum-based chemotherapy and the PARP inhibitor olaparib (Supplementary file of methods).

STM2457 significantly reduced the proliferation and viability of TNBC cells, including both BRCA1/2 wild-type (MDA-MB-231 and MDA-MB-468) and BRCA1-mutated (MDA-MB-436, HCC1395, and HCC1937) cell lines. STM2457 exhibited negligible effects on the proliferation of non-tumoral breast epithelial cells (MCF-10A), with significant reduction observed only at the highest concentration tested (100 μmol/L) (Figure 1A, Supplementary Figure S1A-B). The treatment with 10 μmol/L STM2457 for 48 h decreased the global m6A levels in mRNA by approximately 50% in both MDA-MB-231 and MCF-10A cells (Supplementary Figure S1C). Colony formation assays further confirmed the anti-proliferative impact of STM2457 on TNBC cell lines (Figure 1B, Supplementary Figure S2). Moreover, wound healing assays indicated that

(B) 用 5 μmol/L STM2457(STM)处理 MDA-MB-231 和 MCF-10A 细胞系的细胞集落形成试验。(C) 用伤口愈合试验评估经 20 μmol/L STM2457 处理的 MDA-MB-231 细胞的迁移能力;直方图表示迁移百分比的平均值(± SD),n = 3。(D)MDA-MB-231 细胞经 10 μmol/L STM、10 μmol/L 顺铂或两种药物联合处理 72 小时后的 MTT 检测。(F)MDA-MB-231 细胞经 10 μmol/L STM、20 μmol/L olaparib 或两种药物联合处理 72 小时后的 MTT 检测。(H)48 hpf 斑马鱼胚胎与 MDA-MB-231 GFP 阳性细胞直接移植到 PVS。上图是 CHT 区域的代表性荧光立体显微镜图像,其中包含 24 hpi 外渗的 GFP 阳性细胞,显示了异种移植的 4 个离散等级(高、中、低、无)。侧视图,左前方。下图,评估细胞通过 48 hpf 斑马鱼胚胎异种移植的外渗能力。每个条代表至少两个独立实验计算得出的 24 hpi 幼体的平均值%。分析的胚胎总数为 213 个,划分如下:DMSO(n = 28)、STM(n = 45)、顺铂(n = 37)、顺铂 + STM(n = 53)、奥拉帕利(n = 26)、奥拉帕利 + STM(n = 24)。(I)BCO-21 的代表性明视野图像;下图为苏木精-伊红染色。(J)STM2457 对 BCO-21 的细胞毒性作用。将细胞暴露于不同浓度的药物中 5 天,用 Cell Titer Glo 3D 检测法评估细胞活力。(K)STM2457 和卡铂或奥拉帕利对 BCO 生命力的协同作用。将 BCO-21 暴露于次优剂量(5 μmol/L)和最优剂量(10 μmol/L)的 STM、卡铂(10 μmol/L)和奥拉帕利(10 μmol/L)联合治疗 5 天。计算出药物组合与单个药物相比的 CI 值 < 1(表示协同作用),并显示在图表上方。所有结果均以三重复的平均值 ± SEM 表示。*P < 0.05,**P < 0.01,***P < 0.001。缩写:缩写:BCO,乳腺癌类器官;CHT,尾部造血组织;CI,组合指数;DMSO,二甲基亚砜;GFP,绿色荧光蛋白;Hpf,受精后数小时;Hpi,注射后数小时;MTT,3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四唑;PVS,绒毛膜周围间隙;SD,标准差;SEM,均值标准误差;STM,STM2457。首先,我们研究了 METTL3 抑制与 DNA 损伤药物联合使用的效果。铂类化疗药物和 PARP 抑制剂(如奥拉帕利)对携带 BRCA1/2 基因突变的 TNBC 大多显示出良好的反应[5]。由于 STM2457 下调了参与 DNA 修复途径的基因,我们假设它也可能降低 BRCA1/2 野生型 TNBC 细胞的同源重组(HR)能力。为了验证这一假设,我们研究了抑制 METTL3 对 MDA-MB-231 细胞对顺铂和奥拉帕利反应的影响,MDA-MB-231 细胞是 BRCA1/2 野生型细胞,对 DNA 损伤药物的敏感性较低。用低于半数最大抑制浓度(IC50)的 STM2457、顺铂和奥拉帕利作为单药或联合用药治疗 MDA-MB-231 细胞。与单药治疗相比,STM2457与顺铂或奥拉帕利联合治疗可显著减少MDA-MB-231细胞的增殖并增加细胞凋亡(图1D-G)。值得注意的是,单用 STM2457 就足以诱导 DNA 损伤,H2A 组蛋白家族成员 X(γH2AX)的磷酸化升高就说明了这一点(补充图 S7A-B)。此外,我们还注意到,DNA 损伤后,RecA 相关蛋白 51 (RAD51) 蛋白水平和 RAD51 病灶全面下降(附图 S7C-D)。这些发现与敲除 METTL3 表达的细胞中的发现一致[7, 8]。此外,我们还观察到 DNA 损伤在联合处理后持续大幅增加(补充图 S7A-B)。这些数据共同表明,STM2457能使具有野生型BRCA1/2的HR-proficient TNBC细胞对基因毒性化疗或PARP抑制剂诱导的DNA损伤产生强烈的敏感性。由于STM2457治疗能减少TNBC细胞的迁移,我们进一步探讨了它对癌细胞转移的影响。我们选择了转移性TNBC细胞系MDA-MB-231注射到斑马鱼幼体中,斑马鱼幼体是研究转移的一种成熟的体内异种移植模型[10]。
{"title":"Enhancing sensitivity of triple-negative breast cancer to DNA-damaging therapy through chemical inhibition of the m6A methyltransferase METTL3","authors":"Bianca Cesaro,&nbsp;Alessia Iaiza,&nbsp;Fabio Piscopo,&nbsp;Marco Tarullo,&nbsp;Eleonora Cesari,&nbsp;Dante Rotili,&nbsp;Antonello Mai,&nbsp;Alberto Diana,&nbsp;Michela Londero,&nbsp;Luca Del Giacco,&nbsp;Riccardo Masetti,&nbsp;Alba Di Leone,&nbsp;Chiara Naro,&nbsp;Silvia Masciarelli,&nbsp;Giulia Fontemaggi,&nbsp;Claudio Sette,&nbsp;Francesco Fazi,&nbsp;Alessandro Fatica","doi":"10.1002/cac2.12509","DOIUrl":"10.1002/cac2.12509","url":null,"abstract":"<p>Dear Editor,</p><p>N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) is a critical mRNA modification catalyzed by the enzyme methyltransferase-like 3 (METTL3), with implications in RNA metabolism. METTL3 upregulation is associated with cancer progression, metastasis, and drug resistance, making it a potential therapeutic target [<span>1</span>]. The small-molecule METTL3 inhibitor, STM2457, has shown promise in treating acute myeloid leukemia (AML) and has demonstrated good tolerance in mice [<span>2, 3</span>]. However, the specific cancer types where METTL3 inhibitors are most effective remain unknown.</p><p>In breast cancer, <i>METTL3</i> knockdown markedly suppresses proliferation, invasiveness, and metastasis [<span>4</span>]. Therefore, METTL3 inhibition is proposed as a therapeutic approach for breast cancer. Triple-negative breast cancer (TNBC), the most aggressive subtype, lacks targeted therapies, and its primary treatments involve conventional chemotherapy and DNA-damaging agents [<span>5</span>]. Homologous recombination deficiency, such as mutations in the breast cancer gene 1 (<i>BRCA1</i>) and <i>BRCA2</i>, serves as a predictive biomarker for identifying patients who would benefit from genotoxic chemotherapy and poly(ADP-ribose) polymerase (<i>PARP</i>) inhibitors. Notably, METTL3 is recruited to DNA-damaged sites and is crucial for subsequent DNA repair [<span>6, 7</span>]. Consequently, <i>METTL3</i> knockdown reduces DNA repair activity and sensitizes cancer cells to genotoxic drugs [<span>7, 8</span>]. However, while TNBC exhibits elevated METTL3 levels, and its nuclear catalytic activity associates with invasiveness and metastasis [<span>9</span>], it remains uncertain whether METTL3 inhibition enhances chemotherapy response in TNBC.</p><p>Here, we aimed to explore the potential of METTL3 catalytic inhibition by STM2457 as a valuable treatment option for TNBC. Furthermore, we assessed the impact of STM2457 on the sensitivity of TNBC cells and a TNBC patient-derived organoid line to clinical DNA-damaging therapies, like platinum-based chemotherapy and the PARP inhibitor olaparib (Supplementary file of methods).</p><p>STM2457 significantly reduced the proliferation and viability of TNBC cells, including both <i>BRCA1/2</i> wild-type (MDA-MB-231 and MDA-MB-468) and <i>BRCA1</i>-mutated (MDA-MB-436, HCC1395, and HCC1937) cell lines. STM2457 exhibited negligible effects on the proliferation of non-tumoral breast epithelial cells (MCF-10A), with significant reduction observed only at the highest concentration tested (100 μmol/L) (Figure 1A, Supplementary Figure S1A-B). The treatment with 10 μmol/L STM2457 for 48 h decreased the global m<sup>6</sup>A levels in mRNA by approximately 50% in both MDA-MB-231 and MCF-10A cells (Supplementary Figure S1C). Colony formation assays further confirmed the anti-proliferative impact of STM2457 on TNBC cell lines (Figure 1B, Supplementary Figure S2). Moreover, wound healing assays indicated that ","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":null,"pages":null},"PeriodicalIF":16.2,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12509","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138741751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cover Image, Volume 43, Issue 12 封面图片,第43卷,第12期
IF 16.2 1区 医学 Q1 Medicine Pub Date : 2023-12-02 DOI: 10.1002/cac2.12508
Yuting Li, Hanhao Zheng, Yuming Luo, Yan Lin, Mingjie An, Yao Kong, Yue Zhao, Yina Yin, Le Ai, Jian Huang, Changhao Chen

The cover image is based on the Original Article An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis by Yuting Li et al., https://doi.org/10.1002/cac2.12470.

封面图片来源于李玉婷等人https://doi.org/10.1002/cac2.12470的文章膀胱癌细胞和成纤维细胞之间hgf依赖的正反馈回路介导淋巴管生成和淋巴转移。
{"title":"Cover Image, Volume 43, Issue 12","authors":"Yuting Li,&nbsp;Hanhao Zheng,&nbsp;Yuming Luo,&nbsp;Yan Lin,&nbsp;Mingjie An,&nbsp;Yao Kong,&nbsp;Yue Zhao,&nbsp;Yina Yin,&nbsp;Le Ai,&nbsp;Jian Huang,&nbsp;Changhao Chen","doi":"10.1002/cac2.12508","DOIUrl":"https://doi.org/10.1002/cac2.12508","url":null,"abstract":"<p>The cover image is based on the Original Article <i>An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis</i> by Yuting Li et al., https://doi.org/10.1002/cac2.12470.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":null,"pages":null},"PeriodicalIF":16.2,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12508","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138475622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA-CCAT5-mediated crosstalk between Wnt/β-Catenin and STAT3 signaling suggests novel therapeutic approaches for metastatic gastric cancer with high Wnt activity lncrna - ccat5介导的Wnt/β-Catenin与STAT3信号之间的串扰提示了高Wnt活性转移性胃癌的新治疗方法。
IF 16.2 1区 医学 Q1 Medicine Pub Date : 2023-11-27 DOI: 10.1002/cac2.12507
Chenchen Liu, Aiwen Shen, Junquan Song, Lei Cheng, Meng Zhang, Yanong Wang, Xiaowen Liu

Background

Although the constitutively activated Wnt/β-catenin signaling pathway plays vital roles in gastric cancer (GC) progression, few Wnt inhibitors are approved for clinical use. Additionally, the clinical significance of long non-coding RNAs (lncRNAs) in GC intraperitoneal dissemination (IPD) remains elusive. Here, we investigated the function and therapeutic potential of Wnt-transactivated lncRNA, colon cancer-associated transcript 5 (CCAT5), in GC metastasis.

Methods

LncRNA-sequencing assay was performed to document abundance changes of lncRNAs induced by Wnt family member 3A (Wnt3a) and degradation-resistant β-catenin (S33Y mutated) in ascites-derived GC cells with low Wnt activity. Luciferase reporter, Chromatin immunoprecipitation (ChIP)-re-ChIP assays were performed to determine how CCAT5 was transcribed. The clinical significance of CCAT5 was examined in 2 cohorts of GC patients. The biological function of CCAT5 was investigated through gain- and loss-of-function studies. The molecular mechanism was explored through RNA-sequencing, mass spectrometry, and CRISPR/Cas9-knocknout system. The therapeutic potential of CCAT5 was examined through RNAi-based cell xenograft model and patient-derived xenograft (PDX) model of IPD.

Results

We identified a novel Wnt-regulated lncRNA, CCAT5, which was transactivated by the β-catenin/transcription factor 3 (TCF3) complex. CCAT5 was significantly upregulated in GC and predicted poor prognosis. Functional studies confirmed the promotive role of CCAT5 in GC growth and metastasis. Mechanistically, CCAT5 bound to the C-end domain of signal transducer and activator of transcription 3 (STAT3) and blocks Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP-1)-mediated STAT3Y705 dephosphorylation, leading to STAT3 nuclear entry and transactivation, thus accelerating GC progression. Furthermore, we demonstrated that both Wnt3a and β-catenin acted as activator of STAT3 signaling pathway, and the interplay between CCAT5 and STAT3 was functionally essential for Wnt-drived STAT3 signaling and tumor evolution. Finally, we revealed in vivo si-CCAT5 selectively attenuated growth and metastasis of Wnthigh GC, but not Wntlow GC. The combination of si-CCAT5 and oxaliplatin displayed obvious synergistic therapeutic effects on Wnthigh PDX mice.

Conclusions

We identified a novel Wnt-transactivated lncRNA, CCAT5. Our study r

背景:虽然组成性激活的Wnt/β-catenin信号通路在胃癌(GC)的进展中起着至关重要的作用,但很少有Wnt抑制剂被批准用于临床。此外,长链非编码rna (lncRNAs)在GC腹腔播散(IPD)中的临床意义尚不明确。在这里,我们研究了wnt转激活的lncRNA结肠癌相关转录物5 (CCAT5)在胃癌转移中的功能和治疗潜力。方法:采用lncrna测序法,记录Wnt家族成员3A (Wnt3a)和抗降解β-catenin (S33Y突变)在Wnt活性低的腹水源性GC细胞中诱导的lncrna丰度变化。采用荧光素酶报告基因、染色质免疫沉淀(ChIP)-re-ChIP测定CCAT5的转录方式。在两组胃癌患者中检测CCAT5的临床意义。CCAT5的生物学功能通过功能获得和功能丧失研究进行了研究。通过rna测序、质谱分析和CRISPR/ cas9敲除系统探索其分子机制。通过基于rnai的细胞异种移植模型和IPD患者源异种移植(PDX)模型检测CCAT5的治疗潜力。结果:我们发现了一个新的wnt调控lncRNA CCAT5,它被β-catenin/转录因子3 (TCF3)复合物反激活。CCAT5在GC中显著上调,预示预后不良。功能研究证实了CCAT5在胃癌生长和转移中的促进作用。在机制上,CCAT5结合到信号换能器和转录激活子3 (STAT3)的c端结构域,阻断含有Src同源2结构域的蛋白酪氨酸磷酸酶1 (SHP-1)介导的STAT3Y705去磷酸化,导致STAT3进入核并转激活,从而加速GC的进展。此外,我们证明Wnt3a和β-catenin都是STAT3信号通路的激活剂,并且CCAT5和STAT3之间的相互作用对于wnt驱动的STAT3信号传导和肿瘤进化在功能上是必不可少的。最后,我们发现体内si-CCAT5选择性地抑制Wnthigh GC的生长和转移,但对wnlow GC没有作用。si-CCAT5联合奥沙利铂对Wnthigh PDX小鼠有明显的协同治疗作用。结论:我们发现了一种新的wnt转激活lncRNA CCAT5。我们的研究揭示了STAT3信号通过典型Wnt信号调控的机制,以及CCAT5作为关键中介的功能意义。我们提供了lncrna作为逆转GC进展的治疗靶点的概念进展。
{"title":"LncRNA-CCAT5-mediated crosstalk between Wnt/β-Catenin and STAT3 signaling suggests novel therapeutic approaches for metastatic gastric cancer with high Wnt activity","authors":"Chenchen Liu,&nbsp;Aiwen Shen,&nbsp;Junquan Song,&nbsp;Lei Cheng,&nbsp;Meng Zhang,&nbsp;Yanong Wang,&nbsp;Xiaowen Liu","doi":"10.1002/cac2.12507","DOIUrl":"10.1002/cac2.12507","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Although the constitutively activated Wnt/β-catenin signaling pathway plays vital roles in gastric cancer (GC) progression, few Wnt inhibitors are approved for clinical use. Additionally, the clinical significance of long non-coding RNAs (lncRNAs) in GC intraperitoneal dissemination (IPD) remains elusive. Here, we investigated the function and therapeutic potential of Wnt-transactivated lncRNA, colon cancer-associated transcript 5 (CCAT5), in GC metastasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>LncRNA-sequencing assay was performed to document abundance changes of lncRNAs induced by Wnt family member 3A (Wnt3a) and degradation-resistant β-catenin (S33Y mutated) in ascites-derived GC cells with low Wnt activity. Luciferase reporter, Chromatin immunoprecipitation (ChIP)-re-ChIP assays were performed to determine how CCAT5 was transcribed. The clinical significance of CCAT5 was examined in 2 cohorts of GC patients. The biological function of CCAT5 was investigated through gain- and loss-of-function studies. The molecular mechanism was explored through RNA-sequencing, mass spectrometry, and CRISPR/Cas9-knocknout system. The therapeutic potential of CCAT5 was examined through RNAi-based cell xenograft model and patient-derived xenograft (PDX) model of IPD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified a novel Wnt-regulated lncRNA, CCAT5, which was transactivated by the β-catenin/transcription factor 3 (TCF3) complex. CCAT5 was significantly upregulated in GC and predicted poor prognosis. Functional studies confirmed the promotive role of CCAT5 in GC growth and metastasis. Mechanistically, CCAT5 bound to the C-end domain of signal transducer and activator of transcription 3 (STAT3) and blocks Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP-1)-mediated STAT3<sup>Y705</sup> dephosphorylation, leading to STAT3 nuclear entry and transactivation, thus accelerating GC progression. Furthermore, we demonstrated that both Wnt3a and β-catenin acted as activator of STAT3 signaling pathway, and the interplay between CCAT5 and STAT3 was functionally essential for Wnt-drived STAT3 signaling and tumor evolution. Finally, we revealed in vivo si-CCAT5 selectively attenuated growth and metastasis of Wnt<sup>high</sup> GC, but not Wnt<sup>low</sup> GC. The combination of si-CCAT5 and oxaliplatin displayed obvious synergistic therapeutic effects on Wnt<sup>high</sup> PDX mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We identified a novel Wnt-transactivated lncRNA, CCAT5. Our study r","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":null,"pages":null},"PeriodicalIF":16.2,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12507","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138443897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell and bulk transcriptomics identifies a tumor-specific CD36+ cancer-associated fibroblast subpopulation in colorectal cancer. 单细胞和大量转录组学鉴定结直肠癌中肿瘤特异性CD36+癌症相关成纤维细胞亚群。
IF 16.2 1区 医学 Q1 Medicine Pub Date : 2023-11-21 DOI: 10.1002/cac2.12506
Jin Wang, Ming-Jia Xi, Qing Lu, Bi-Han Xia, Yu-Zhi Liu, Jin-Lin Yang
{"title":"Single-cell and bulk transcriptomics identifies a tumor-specific CD36<sup>+</sup> cancer-associated fibroblast subpopulation in colorectal cancer.","authors":"Jin Wang, Ming-Jia Xi, Qing Lu, Bi-Han Xia, Yu-Zhi Liu, Jin-Lin Yang","doi":"10.1002/cac2.12506","DOIUrl":"https://doi.org/10.1002/cac2.12506","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":null,"pages":null},"PeriodicalIF":16.2,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138290446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multi-omic study to unmask genes involved in prostate cancer development in a multi-case family 多组学研究揭示了多病例家族中前列腺癌发展的基因。
IF 16.2 1区 医学 Q1 Medicine Pub Date : 2023-11-21 DOI: 10.1002/cac2.12501
Lucia Chica-Redecillas, Sergio Cuenca-Lopez, Eduardo Andres-Leon, Laura Carmen Terron-Camero, Blanca Cano-Gutierrez, Jose Manuel Cozar, Jose Antonio Lorente, Fernando Vazquez-Alonso, Luis Javier Martinez-Gonzalez, Maria Jesus Alvarez-Cubero

Dear Editor,

Hereditary prostate cancer (PC) comprises 5%-10% of all PC cases. The increased risk of PC in men with a family history of the disease is well known and is commonly caused by germline mutations, leading to clinical guidelines mentioning various genes for identifying high-risk individuals. However, the complex inheritance patterns involving multiple single nucleotide polymorphisms (SNPs) make it a genetically heterogeneous disease, with genetic testing still in its early stages. Current guidelines, such as those from the National Comprehensive Cancer Network (NCCN), are insufficient to identify and stratify all PC patients [1]. To improve testing and screening for familial PC, we report a multi-omic analysis (Supplementary Figures S1-S2) in a PC multi-case family of seven members (two healthy, four PC, and one breast cancer) (Figure 1A, Supplementary Table S1) combining exome, transcriptome and epigenomic analyses (whole-DNA methylation and small-RNA sequencing), offering a unique perspective on the understanding of hereditary PC to date. Each family is a small genetic unit that differs significantly from others with the same pathology but different genetic origins. Therefore, individualized studies may be the key to unravel the heterogeneity of this disease. However, we need to consider that conducting futuremetabolomic analysis would be next steps to reinforce present data, as well as reproducible analysis in other PC families.

We selected 34 genes based on NCCN (v1.2023) and European Association of Urology (EAU, v2.0) clinical guidelines and literature [2, 3] (Supplementary Table S2). We found 268 variants in 26 of these genes (APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1/2, CDH1, CDK4, CHEK2, DICER1, MLH1, MSH2/3/6, MUTYH, NF1, PMS2, POLD1, POLE, PTEN, RAD51C/D, SMAD4, STK11 and TP53), most of which were intronic (91.4%) and/or unreported (84.3%) (Supplementary Figure S3 and Supplementary Table S3). In addition, genome-wide analysis of high-impact variants revealed only four mutations affecting the major isoforms of the ANAPC1, HIBCH, and MOK, but none of these genes have been previously reported in PC (Supplementary Table S4). Interestingly, despite being high-risk cancer patients, the individuals in the present study's family did not show any pathogenic mutations in the genes specified by clinical guidelines. Furthermore, this is added to the growing evidence for the potential of non-coding mutations, both near-exonic and deep-intronic mutations, in carcinogenesis. There is already evidence of how known tumor suppressor genes are affected by intronic mutations [4]. Exome analysis also reported ten identical mutations in three genes, one in AXIN2, two in DICER1 and seven in BARD1, in all PC patients (Supplementary Table S3), suggesting that these mutations may be responsible for the development of cancer in this family. Among th

亲爱的编辑,遗传性前列腺癌(PC)占所有 PC 病例的 5%-10%。众所周知,有家族病史的男性罹患前列腺癌的风险会增加,这通常是由种系突变引起的,因此临床指南中提到了用于识别高危人群的各种基因。然而,涉及多个单核苷酸多态性(SNP)的复杂遗传模式使其成为一种遗传异质性疾病,基因检测仍处于早期阶段。美国国家综合癌症网络(NCCN)等机构制定的现行指南不足以对所有 PC 患者进行识别和分层[1]。为了改善家族性 PC 的检测和筛查,我们报告了一个由 7 名成员(2 名健康、4 名 PC 和 1 名乳腺癌)组成的 PC 多病例家族(图 1A,补充表 S1)的多组学分析(补充图 S1-S2),该分析结合了外显子组、转录组和表观基因组分析(全 DNA 甲基化和小 RNA 测序),为迄今为止对遗传性 PC 的了解提供了一个独特的视角。每个家族都是一个小的遗传单元,与病理相同但遗传起源不同的其他家族有显著差异。因此,个体化研究可能是揭示这种疾病异质性的关键。我们根据 NCCN(v1.2023)和欧洲泌尿外科协会(EAU,v2.0)的临床指南和文献[2, 3]选择了 34 个基因(补充表 S2)。我们在其中 26 个基因(APC、ATM、AXIN2、BARD1、BMPR1A、BRCA1/2、CDH1、CDK4、CHEK2、DICER1、MLH1、MSH2/3/6、MUTYH、NF1、PMS2、POLD1、POLE、PTEN、RAD51C/D、SMAD4、STK11 和 TP53)中发现了 268 个变异,其中大部分为内含子(91.4%)和/或未报告(84.3%)(补充图 S3 和补充表 S3)。此外,对高影响变异的全基因组分析显示,只有 4 个突变影响到 ANAPC1、HIBCH 和 MOK 的主要同工酶,但这些基因以前都未在 PC 中报道过(补充表 S4)。有趣的是,尽管是高危癌症患者,本研究中的家族成员并没有出现临床指南中规定的致病基因突变。此外,越来越多的证据表明,非编码突变(包括近外显子突变和深内显子突变)在致癌过程中具有潜在作用。已有证据表明,已知的肿瘤抑制基因会受到内含子突变的影响[4]。外显子组分析还报告了所有 PC 患者中三个基因的十个相同突变,其中一个在 AXIN2,两个在 DICER1,七个在 BARD1(补充表 S3),这表明这些突变可能是该家族癌症发生的原因。在这十个相同的突变中,BARD1 中的三个突变(c.2001+66A&gt;C、c.1811-69T&gt;C 和 c.1811-77A&gt;G)和 AXIN2 中的一个突变(c.-116-1330C&gt;G)在欧洲人群中的频率低于 0.05。接下来,我们主要关注与β-catenin通路相互作用的新型遗传标记--AXIN2和DICER1,但也提到了其他相关数据。AXIN2和APC作为β-catenin破坏复合体的一部分,在Wnt信号通路中发挥着重要作用。AXIN2 和 APC 作为 β-catenin 破坏复合体的一部分,在 Wnt 信号通路中发挥着重要作用。部分或完全丧失这些基因的活性会导致 β-catenin 活性增加,从而导致靶基因异常激活,促进细胞增殖和存活(图 1B)[5]。最近,DICER1也被认为是β-catenin的靶基因。此外,在肝脏肿瘤中,DICER1 的突变与 β-catenin 的突变相关,导致其被激活。在子宫内膜样癌和分化良好的胎儿肺腺癌中也观察到了这两个基因同时发生突变的现象[6]。基于这一科学背景,我们在所研究的癌症患者中发现了相同的β-catenin突变(c.*13-8742G&gt;A)。这种内含子突变出现在该基因的无义介导衰变异构体(CTNNB1-212)中,可能会影响该基因的调控和质量控制,防止转录错误[7]。APC 或 β-catenin 突变导致的 Wnt 信号激活已在多种癌症类型中被观察到,在高达 22% 的阉割耐药 PC 中也被观察到 [8]。转录组研究显示,β-catenin 的靶基因 ALDH1A1 明显过表达(P 值 = 2.816 × 10-5,Log2-fold change (logFC) = 1.638)[9],而β-catenin 的表达与 PC 进展过程中的致癌转化有关(补充表 S5)。据观察,KIFC1、RRM2 和 CYP1B1 的过表达可激活 Wnt 信号通路。
{"title":"Multi-omic study to unmask genes involved in prostate cancer development in a multi-case family","authors":"Lucia Chica-Redecillas,&nbsp;Sergio Cuenca-Lopez,&nbsp;Eduardo Andres-Leon,&nbsp;Laura Carmen Terron-Camero,&nbsp;Blanca Cano-Gutierrez,&nbsp;Jose Manuel Cozar,&nbsp;Jose Antonio Lorente,&nbsp;Fernando Vazquez-Alonso,&nbsp;Luis Javier Martinez-Gonzalez,&nbsp;Maria Jesus Alvarez-Cubero","doi":"10.1002/cac2.12501","DOIUrl":"10.1002/cac2.12501","url":null,"abstract":"<p>Dear Editor,</p><p>Hereditary prostate cancer (PC) comprises 5%-10% of all PC cases. The increased risk of PC in men with a family history of the disease is well known and is commonly caused by germline mutations, leading to clinical guidelines mentioning various genes for identifying high-risk individuals. However, the complex inheritance patterns involving multiple single nucleotide polymorphisms (SNPs) make it a genetically heterogeneous disease, with genetic testing still in its early stages. Current guidelines, such as those from the National Comprehensive Cancer Network (NCCN), are insufficient to identify and stratify all PC patients [<span>1</span>]. To improve testing and screening for familial PC, we report a multi-omic analysis (Supplementary Figures S1-S2) in a PC multi-case family of seven members (two healthy, four PC, and one breast cancer) (Figure 1A, Supplementary Table S1) combining exome, transcriptome and epigenomic analyses (whole-DNA methylation and small-RNA sequencing), offering a unique perspective on the understanding of hereditary PC to date. Each family is a small genetic unit that differs significantly from others with the same pathology but different genetic origins. Therefore, individualized studies may be the key to unravel the heterogeneity of this disease. However, we need to consider that conducting futuremetabolomic analysis would be next steps to reinforce present data, as well as reproducible analysis in other PC families.</p><p>We selected 34 genes based on NCCN (v1.2023) and European Association of Urology (EAU, v2.0) clinical guidelines and literature [<span>2, 3</span>] (Supplementary Table S2). We found 268 variants in 26 of these genes (<i>APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1/2, CDH1, CDK4, CHEK2, DICER1, MLH1, MSH2/3/6, MUTYH, NF1, PMS2, POLD1, POLE, PTEN, RAD51C/D, SMAD4, STK11</i> and <i>TP53</i>), most of which were intronic (91.4%) and/or unreported (84.3%) (Supplementary Figure S3 and Supplementary Table S3). In addition, genome-wide analysis of high-impact variants revealed only four mutations affecting the major isoforms of the <i>ANAPC1</i>, <i>HIBCH</i>, and <i>MOK</i>, but none of these genes have been previously reported in PC (Supplementary Table S4). Interestingly, despite being high-risk cancer patients, the individuals in the present study's family did not show any pathogenic mutations in the genes specified by clinical guidelines. Furthermore, this is added to the growing evidence for the potential of non-coding mutations, both near-exonic and deep-intronic mutations, in carcinogenesis. There is already evidence of how known tumor suppressor genes are affected by intronic mutations [<span>4</span>]. Exome analysis also reported ten identical mutations in three genes, one in <i>AXIN2</i>, two in <i>DICER1</i> and seven in <i>BARD1</i>, in all PC patients (Supplementary Table S3), suggesting that these mutations may be responsible for the development of cancer in this family. Among th","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":null,"pages":null},"PeriodicalIF":16.2,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12501","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138290445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of locally advanced non-small cell lung cancer: State of the art and future directions 局部晚期非小细胞肺癌的治疗:现状和未来方向。
IF 16.2 1区 医学 Q1 Medicine Pub Date : 2023-11-20 DOI: 10.1002/cac2.12505
Da Miao, Jing Zhao, Ying Han, Jiaqi Zhou, Xiuzhen Li, Ting Zhang, Wen Li, Yang Xia

Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinically, non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer; approximately one-third of affected patients have locally advanced NSCLC (LA-NSCLC, stage III NSCLC) at diagnosis. Because of its heterogeneity, LA-NSCLC often requires multidisciplinary assessment. Moreover, the prognosis of affected patients is much below satisfaction, and the efficacy of traditional therapeutic strategies has reached a plateau. With the emergence of targeted therapies and immunotherapies, as well as the continuous development of novel radiotherapies, we have entered an era of novel treatment paradigm for LA-NSCLC. Here, we reviewed the landscape of relevant therapeutic modalities, including adjuvant, neoadjuvant, and perioperative targeted and immune strategies in patients with resectable LA-NSCLC with/without oncogenic alterations; as well as novel combinations of chemoradiation and immunotherapy/targeted therapy in unresectable LA-NSCLC. We addressed the unresolved challenges that remain in the field, and examined future directions to optimize clinical management and increase the cure rate of LA-NSCLC.

肺癌是世界上第二常见和最致命的癌症。非小细胞肺癌(NSCLC)是临床上最常见的肺癌病理类型;大约三分之一的受影响患者在诊断时为局部晚期NSCLC (LA-NSCLC, III期NSCLC)。由于其异质性,LA-NSCLC通常需要多学科评估。此外,患者的预后远低于满意,传统治疗策略的疗效已达到平台期。随着靶向治疗和免疫治疗的出现,以及新型放射治疗的不断发展,我们已经进入了LA-NSCLC新治疗范式的时代。在这里,我们回顾了相关治疗方式的前景,包括辅助、新辅助、围手术期靶向和免疫策略在可切除的LA-NSCLC患者中有/没有致癌改变;以及不可切除的LA-NSCLC的放化疗和免疫治疗/靶向治疗的新组合。我们解决了该领域尚未解决的挑战,并研究了优化临床管理和提高LA-NSCLC治愈率的未来方向。
{"title":"Management of locally advanced non-small cell lung cancer: State of the art and future directions","authors":"Da Miao,&nbsp;Jing Zhao,&nbsp;Ying Han,&nbsp;Jiaqi Zhou,&nbsp;Xiuzhen Li,&nbsp;Ting Zhang,&nbsp;Wen Li,&nbsp;Yang Xia","doi":"10.1002/cac2.12505","DOIUrl":"10.1002/cac2.12505","url":null,"abstract":"<p>Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinically, non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer; approximately one-third of affected patients have locally advanced NSCLC (LA-NSCLC, stage III NSCLC) at diagnosis. Because of its heterogeneity, LA-NSCLC often requires multidisciplinary assessment. Moreover, the prognosis of affected patients is much below satisfaction, and the efficacy of traditional therapeutic strategies has reached a plateau. With the emergence of targeted therapies and immunotherapies, as well as the continuous development of novel radiotherapies, we have entered an era of novel treatment paradigm for LA-NSCLC. Here, we reviewed the landscape of relevant therapeutic modalities, including adjuvant, neoadjuvant, and perioperative targeted and immune strategies in patients with resectable LA-NSCLC with/without oncogenic alterations; as well as novel combinations of chemoradiation and immunotherapy/targeted therapy in unresectable LA-NSCLC. We addressed the unresolved challenges that remain in the field, and examined future directions to optimize clinical management and increase the cure rate of LA-NSCLC.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":null,"pages":null},"PeriodicalIF":16.2,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12505","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138175681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cover Image, Volume 43, Issue 11 封面图片,第43卷,第11期
IF 16.2 1区 医学 Q1 Medicine Pub Date : 2023-11-08 DOI: 10.1002/cac2.12504
Ai Zhuang, Xiang Gu, Tongxin Ge, Shaoyun Wang, Shengfang Ge, Peiwei Chai, Renbing Jia, Xianqun Fan

The cover image is based on the Original Article Targeting histone deacetylase suppresses tumor growth through eliciting METTL14-modified m6A RNA methylation in ocular melanoma by Ai Zhuang et al., https://doi.org/10.1002/cac2.12471.

封面图片来源于艾庄等人,https://doi.org/10.1002/cac2.12471的文章《靶向组蛋白去乙酰化酶通过诱导mettl14修饰的m6A RNA甲基化抑制眼部黑色素瘤生长》。
{"title":"Cover Image, Volume 43, Issue 11","authors":"Ai Zhuang,&nbsp;Xiang Gu,&nbsp;Tongxin Ge,&nbsp;Shaoyun Wang,&nbsp;Shengfang Ge,&nbsp;Peiwei Chai,&nbsp;Renbing Jia,&nbsp;Xianqun Fan","doi":"10.1002/cac2.12504","DOIUrl":"https://doi.org/10.1002/cac2.12504","url":null,"abstract":"<p>The cover image is based on the Original Article <i>Targeting histone deacetylase suppresses tumor growth through eliciting METTL14-modified m<sup>6</sup>A RNA methylation in ocular melanoma</i> by Ai Zhuang et al., https://doi.org/10.1002/cac2.12471.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":null,"pages":null},"PeriodicalIF":16.2,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12504","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137811202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cover Image, Volume 43, Issue 11 封面图片,第43卷,第11期
IF 16.2 1区 医学 Q1 Medicine Pub Date : 2023-11-08 DOI: 10.1002/cac2.12503
Yongzhan Nie, Xianchun Gao, Xiqiang Cai, Zhen Wu, Qiaoyi Liang, Guobing Xu, Na Liu, Peng Gao, Jingyu Deng, Hongzhi Xu, Zhanlong Shen, Changqi Cao, Fenrong Chen, Nannan Zhang, Yongxi Song, Mingjun Sun, Chengyin Liu, Guangpeng Zhou, Weili Han, Jianhua Dou, Huahong Xie, Liping Yao, Zhiguo Liu, Gang Ji, Xin Wang, Qingchuan Zhao, Lei Shang, Daiming Fan, Xiaoliang Han, Jianlin Ren, Han Liang, Zhenning Wang, Jinhai Wang, Qi Wu, Jun Yu, Kaichun Wu, the MAGIS Study Group

The cover image is based on the Correspondence Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer by Yongzhan Nie et al., https://doi.org/10.1002/cac2.12478.

封面图片是基于聂永展等人https://doi.org/10.1002/cac2.12478的甲基化SEPTIN9与RNF180血浆标志物的对应组合用于胃癌的诊断和早期检测。
{"title":"Cover Image, Volume 43, Issue 11","authors":"Yongzhan Nie,&nbsp;Xianchun Gao,&nbsp;Xiqiang Cai,&nbsp;Zhen Wu,&nbsp;Qiaoyi Liang,&nbsp;Guobing Xu,&nbsp;Na Liu,&nbsp;Peng Gao,&nbsp;Jingyu Deng,&nbsp;Hongzhi Xu,&nbsp;Zhanlong Shen,&nbsp;Changqi Cao,&nbsp;Fenrong Chen,&nbsp;Nannan Zhang,&nbsp;Yongxi Song,&nbsp;Mingjun Sun,&nbsp;Chengyin Liu,&nbsp;Guangpeng Zhou,&nbsp;Weili Han,&nbsp;Jianhua Dou,&nbsp;Huahong Xie,&nbsp;Liping Yao,&nbsp;Zhiguo Liu,&nbsp;Gang Ji,&nbsp;Xin Wang,&nbsp;Qingchuan Zhao,&nbsp;Lei Shang,&nbsp;Daiming Fan,&nbsp;Xiaoliang Han,&nbsp;Jianlin Ren,&nbsp;Han Liang,&nbsp;Zhenning Wang,&nbsp;Jinhai Wang,&nbsp;Qi Wu,&nbsp;Jun Yu,&nbsp;Kaichun Wu,&nbsp;the MAGIS Study Group","doi":"10.1002/cac2.12503","DOIUrl":"https://doi.org/10.1002/cac2.12503","url":null,"abstract":"<p>The cover image is based on the Correspondence <i>Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer</i> by Yongzhan Nie et al., https://doi.org/10.1002/cac2.12478.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":null,"pages":null},"PeriodicalIF":16.2,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12503","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137811201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondria-targeted atovaquone promotes anti-lung cancer immunity by reshaping tumor microenvironment and enhancing energy metabolism of anti-tumor immune cells 线粒体靶向atovaquone通过重塑肿瘤微环境和增强抗肿瘤免疫细胞的能量代谢来促进抗肺癌癌症免疫。
IF 16.2 1区 医学 Q1 Medicine Pub Date : 2023-11-06 DOI: 10.1002/cac2.12500
Donghai Xiong, Zheng Yin, Mofei Huang, Yian Wang, Micael Hardy, Balaraman Kalyanaraman, Stephen T Wong, Ming You

Atovaquone (ATO), a mitochondrial inhibitor, has anti-cancer effects [1]. Based on ATO, we developed mitochondria-targeted atovaquone (Mito-ATO) that had even stronger anti-tumor efficacy than ATO [2]. We synthesized Mito-ATO by attaching the bulky triphenylphosphonium (TPP) group to ATO via a ten-carbon alkyl chain (Supplementary file of methods; Supplementary Figure S1). To assess the effects of Mito-ATO on tumor microenvironment, we conducted single-cell RNA-sequencing (scRNA-seq) on treated immune cells from mice having lung tumors either treated with or without Mito-ATO. Seurat was used for clustering and annotation of CD45+ immune cells [3]. The detected lymphoid cell populations were CD8+ T cells, CD4+ T cells, regulatory T cells (Tregs), gamma-delta T (Tgd) cells, B cells, and natural killer (NK) cells; and the myeloid cells identified were macrophages, neutrophils, plasmacytoid dendritic cells (pDCs), conventional dendritic cells (cDCs) and mast cells (Figure 1A-C). Clustering of CD4+ T cells into seven subpopulations, the separation of neutrophils and granulocytic myeloid-derived suppressor cells (G-MDSCs), and the division of macrophages into M1 and M2 subtypes were described in our previous publication [2]. In this study, we further divided CD8+ T cells into four subpopulations, i.e., exhausted CD8+ T (CD8T_Exhausted) cells, memory like CD8+ T (CD8T_MemoryLike) cells, effector memory like CD8+ T (CD8T_EffectorMemory) cells and naive CD8+ T (CD8T_Naive) cells, using the tumor-infiltrating CD8+ lymphocyte state predictor (TILPRED) method [4] (Figure 1D-E). Probability scores computed with TILPRED could discriminate CD8T_Exhausted from CD8T_MemoryLike cells despite overlap between the two subsets on UMAP representation (Supplementary Figure S2). Mito-ATO treatment significantly decreased the proportion of the CD8T_Exhausted cells (7.3% vs. 32.5%, P < 0.001) but increased the proportion of anti-tumor CD8T_EffectorMemory cells as compared with vehicle treatment (37.3% vs. 11.9%, P < 0.001) (Figure 1F). In comparison, the percentages of CD8+ T cells out of total T cells were not different between the two groups (Supplementary Table S1). For validation, we verified that Mito-ATO treatment induced changes in CD8+ T cell repartition by conducting flow cytometry. Mito-ATO treatment significantly increased the percentage of cytotoxic tumor necrosis factor-alpha (TNF-α)+CD8+ T cells and decreased the percentage of programmed cell death protein-1 (PD-1)+ T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)+CD8+ T cells (Supplementary Figure S3). These matched the scRNA-seq results. We also observed a slight trend toward the upregulation of genes involved in CD8

线粒体抑制剂阿托伐醌(ATO)具有抗癌作用[1]。在 ATO 的基础上,我们开发出了线粒体靶向阿托伐醌(Mitochondria-targeted atovaquone,Mito-ATO),其抗肿瘤效果比 ATO 更强[2]。我们通过一条十碳烷基链将笨重的三苯基膦(TPP)基团连接到 ATO 上,从而合成了 Mito-ATO(方法的补充文件;补充图 S1)。为了评估Mito-ATO对肿瘤微环境的影响,我们对肺肿瘤小鼠的免疫细胞进行了单细胞RNA测序(scRNA-seq),这些免疫细胞有的接受过Mito-ATO治疗,有的没有。采用 Seurat 对 CD45+ 免疫细胞进行聚类和注释 [3]。检测到的淋巴细胞群包括 CD8+ T 细胞、CD4+ T 细胞、调节性 T 细胞(Tregs)、γ-δ T 细胞(Tgd)、B 细胞和自然杀伤(NK)细胞;检测到的骨髓细胞包括巨噬细胞、中性粒细胞、浆细胞树突状细胞(pDCs)、传统树突状细胞(cDCs)和肥大细胞(图 1A-C)。CD4+T细胞聚类为七个亚群,中性粒细胞和粒细胞髓源性抑制细胞(G-MDSCs)分离,巨噬细胞分为M1和M2亚型,这些在我们之前发表的文章中都有描述[2]。在本研究中,我们进一步将 CD8+ T 细胞分为四个亚群,即我们使用肿瘤浸润 CD8+ 淋巴细胞状态预测法(TILPRED)[4]进一步将 CD8+ T 细胞分为四个亚群,即衰竭 CD8+ T(CD8T_Exhausted)细胞、记忆 CD8+ T(CD8T_MemoryLike)细胞、效应记忆 CD8+ T(CD8T_EffectorMemory)细胞和幼稚 CD8+ T(CD8T_Naive)细胞(图 1D-E)。尽管CD8T_Exhausted和CD8T_MemoryLike两个亚群在UMAP表征上有重叠,但用TILPRED计算的概率分数可以区分这两个亚群(补充图S2)。与车辆处理相比,Mito-ATO 处理明显降低了 CD8T_Exhausted 细胞的比例(7.3% vs. 32.5%,P &lt; 0.001),但增加了抗肿瘤 CD8T_EffectorMemory 细胞的比例(37.3% vs. 11.9%,P &lt; 0.001)(图 1F)。相比之下,两组 CD8+ T 细胞占 T 细胞总数的百分比没有差异(补充表 S1)。为了进行验证,我们通过流式细胞术验证了米托-ATO 治疗诱导了 CD8+ T 细胞重新分区的变化。米托-ATO治疗明显增加了细胞毒性肿瘤坏死因子-α(TNF-α)+CD8+ T细胞的比例,降低了程序性细胞死亡蛋白-1(PD-1)+ T细胞免疫球蛋白和含粘蛋白结构域蛋白3(TIM3)+CD8+ T细胞的比例(补充图S3)。这些结果与 scRNA-seq 的结果相吻合。我们还观察到参与 CD8+ T 细胞招募的基因有轻微的上调趋势:Ccl25、Ccr7、Cxcl10、Cxcr3、Icam1和S1pr1(补充图S4)。米托-ATO处理显著上调了四个抗肿瘤免疫细胞群的氧化磷酸化(OXPHOS)活性,即CD8T_EffectorMemory细胞、CD8T_MemoryLike细胞、细胞毒性CD4+ T细胞(CD4T_Cytotoxic)和M1巨噬细胞(图1G)。特别是,经 Mito-ATO 处理后上调的基因明显富集于 T 细胞分化(补充图 S5),表明 Mito-ATO 处理可能诱导 CD8+ T 细胞分化。相比之下,Mito-ATO 处理显著下调了五种促肿瘤免疫细胞群的 OXPHOS 活性,即白细胞介素-2 受体亚基α(IL2RA)-低的 CD4+ (CD4IL2RALO)Tregs、G-MDSCs、肥大细胞、IL2RA-高的 CD4+ (CD4IL2RAHI)Tregs 和衰竭的 CD4+ T 细胞(CD4T_Exhausted)(图 1G)。这两种类型的 Treg 细胞是按照以往的做法命名的[2, 5]。在上述免疫细胞群中,有十种代谢途径的活性变化与经 Mito-ATO 处理后的 OXPHOS 活性变化相似。这些途径分别是糖酵解、三羧酸(TCA)循环、丙酮酸代谢、谷氨酰胺代谢、复合体 I、复合体 III、复合体 V、DNA 修复、嘌呤代谢和嘧啶代谢(图 1G)。DNA损伤、细胞凋亡、细胞死亡和活性氧(ROS)途径等四种细胞死亡相关途径的变化与OXPHOS活性的变化呈负相关(图1G)。Compass 代谢分析[6]显示了类似的结果(补充图 S6-S14)。TCA 循环和谷氨酰胺代谢的关键代谢反应在抗肿瘤免疫细胞群中上调,而在促肿瘤免疫细胞群中下调(图 1H-I)。
{"title":"Mitochondria-targeted atovaquone promotes anti-lung cancer immunity by reshaping tumor microenvironment and enhancing energy metabolism of anti-tumor immune cells","authors":"Donghai Xiong,&nbsp;Zheng Yin,&nbsp;Mofei Huang,&nbsp;Yian Wang,&nbsp;Micael Hardy,&nbsp;Balaraman Kalyanaraman,&nbsp;Stephen T Wong,&nbsp;Ming You","doi":"10.1002/cac2.12500","DOIUrl":"10.1002/cac2.12500","url":null,"abstract":"<p>Atovaquone (ATO), a mitochondrial inhibitor, has anti-cancer effects [<span>1</span>]. Based on ATO, we developed mitochondria-targeted atovaquone (Mito-ATO) that had even stronger anti-tumor efficacy than ATO [<span>2</span>]. We synthesized Mito-ATO by attaching the bulky triphenylphosphonium (TPP) group to ATO via a ten-carbon alkyl chain (Supplementary file of methods; Supplementary Figure S1). To assess the effects of Mito-ATO on tumor microenvironment, we conducted single-cell RNA-sequencing (scRNA-seq) on treated immune cells from mice having lung tumors either treated with or without Mito-ATO. Seurat was used for clustering and annotation of CD45<sup>+</sup> immune cells [<span>3</span>]. The detected lymphoid cell populations were CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, regulatory T cells (Tregs), gamma-delta T (Tgd) cells, B cells, and natural killer (NK) cells; and the myeloid cells identified were macrophages, neutrophils, plasmacytoid dendritic cells (pDCs), conventional dendritic cells (cDCs) and mast cells (Figure 1A-C). Clustering of CD4<sup>+</sup> T cells into seven subpopulations, the separation of neutrophils and granulocytic myeloid-derived suppressor cells (G-MDSCs), and the division of macrophages into M1 and M2 subtypes were described in our previous publication [<span>2</span>]. In this study, we further divided CD8<sup>+</sup> T cells into four subpopulations, i.e., exhausted CD8<sup>+</sup> T (CD8T_Exhausted) cells, memory like CD8<sup>+</sup> T (CD8T_MemoryLike) cells, effector memory like CD8<sup>+</sup> T (CD8T_EffectorMemory) cells and naive CD8<sup>+</sup> T (CD8T_Naive) cells, using the tumor-infiltrating CD8<sup>+</sup> lymphocyte state predictor (TILPRED) method [<span>4</span>] (Figure 1D-E). Probability scores computed with TILPRED could discriminate CD8T_Exhausted from CD8T_MemoryLike cells despite overlap between the two subsets on UMAP representation (Supplementary Figure S2). Mito-ATO treatment significantly decreased the proportion of the CD8T_Exhausted cells (7.3% vs. 32.5%, <i>P</i> &lt; 0.001) but increased the proportion of anti-tumor CD8T_EffectorMemory cells as compared with vehicle treatment (37.3% vs. 11.9%, <i>P</i> &lt; 0.001) (Figure 1F). In comparison, the percentages of CD8<sup>+</sup> T cells out of total T cells were not different between the two groups (Supplementary Table S1). For validation, we verified that Mito-ATO treatment induced changes in CD8<sup>+</sup> T cell repartition by conducting flow cytometry. Mito-ATO treatment significantly increased the percentage of cytotoxic tumor necrosis factor-alpha (TNF-α)<sup>+</sup>CD8<sup>+</sup> T cells and decreased the percentage of programmed cell death protein-1 (PD-1)<sup>+</sup> T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)<sup>+</sup>CD8<sup>+</sup> T cells (Supplementary Figure S3). These matched the scRNA-seq results. We also observed a slight trend toward the upregulation of genes involved in CD8<su","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":null,"pages":null},"PeriodicalIF":16.2,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12500","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71478363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma EGFR/AKT和甲羟戊酸途径的阻断通过重新编程胶质母细胞瘤中的能量代谢协同替莫唑胺的抗肿瘤作用。
IF 16.2 1区 医学 Q1 Medicine Pub Date : 2023-11-02 DOI: 10.1002/cac2.12502
Xiaoteng Cui, Jixing Zhao, Guanzhang Li, Chao Yang, Shixue Yang, Qi Zhan, Junhu Zhou, Yunfei Wang, Menglin Xiao, Biao Hong, Kaikai Yi, Fei Tong, Yanli Tan, Hu Wang, Qixue Wang, Tao Jiang, Chuan Fang, Chunsheng Kang

Background

Metabolism reprogramming plays a vital role in glioblastoma (GBM) progression and recurrence by producing enough energy for highly proliferating tumor cells. In addition, metabolic reprogramming is crucial for tumor growth and immune-escape mechanisms. Epidermal growth factor receptor (EGFR) amplification and EGFR-vIII mutation are often detected in GBM cells, contributing to the malignant behavior. This study aimed to investigate the functional role of the EGFR pathway on fatty acid metabolism remodeling and energy generation.

Methods

Clinical GBM specimens were selected for single-cell RNA sequencing and untargeted metabolomics analysis. A metabolism-associated RTK-fatty acid-gene signature was constructed and verified. MK-2206 and MK-803 were utilized to block the RTK pathway and mevalonate pathway induced abnormal metabolism. Energy metabolism in GBM with activated EGFR pathway was monitored. The antitumor effect of Osimertinib and Atorvastatin assisted by temozolomide (TMZ) was analyzed by an intracranial tumor model in vivo.

Results

GBM with high EGFR expression had characteristics of lipid remodeling and maintaining high cholesterol levels, supported by the single-cell RNA sequencing and metabolomics of clinical GBM samples. Inhibition of the EGFR/AKT and mevalonate pathways could remodel energy metabolism by repressing the tricarboxylic acid cycle and modulating ATP production. Mechanistically, the EGFR/AKT pathway upregulated the expressions of acyl-CoA synthetase short-chain family member 3 (ACSS3), acyl-CoA synthetase long-chain family member 3 (ACSL3), and long-chain fatty acid elongation-related gene ELOVL fatty acid elongase 2 (ELOVL2) in an NF-κB-dependent manner. Moreover, inhibition of the mevalonate pathway reduced the EGFR level on the cell membranes, thereby affecting the signal transduction of the EGFR/AKT pathway. Therefore, targeting the EGFR/AKT and mevalonate pathways enhanced the antitumor effect of TMZ in GBM cells and animal models.

Conclusions

Our findings not only uncovered the mechanism of metabolic reprogramming in EGFR-activated GBM but also provided a combinatorial therapeutic strategy for clinical GBM management.

背景:代谢重编程通过为高度增殖的肿瘤细胞产生足够的能量,在胶质母细胞瘤(GBM)的进展和复发中起着至关重要的作用。此外,代谢重编程对肿瘤生长和免疫逃逸机制至关重要。在GBM细胞中经常检测到表皮生长因子受体(EGFR)扩增和EGFRvIII突变,从而导致恶性行为。本研究旨在探讨EGFR通路在脂肪酸代谢重塑和能量生成中的功能作用。方法:选择临床GBM标本进行单细胞RNA测序和非靶向代谢组学分析。构建并验证了代谢相关的RTK脂肪酸基因特征。MK-2206和MK-803阻断RTK途径和甲羟戊酸途径诱导的代谢异常。通过激活EGFR途径监测GBM的能量代谢。通过颅内肿瘤模型分析了奥西美替尼和阿托伐他汀在替莫唑胺(TMZ)辅助下的抗肿瘤作用。结果:临床GBM样本的单细胞RNA测序和代谢组学支持了EGFR高表达的GBM具有脂质重塑和维持高胆固醇水平的特征。抑制EGFR/AKT和甲羟戊酸途径可以通过抑制三羧酸循环和调节ATP产生来重塑能量代谢。从机制上讲,EGFR/AKT途径以NF-κB依赖的方式上调酰基辅酶A合成酶短链家族成员3(ACSS3)、酰基辅酶A合成酶长链家族成员三(ACSL3)和长链脂肪酸延伸相关基因ELOVL脂肪酸延伸酶2(ELOVL2)的表达。此外,甲羟戊酸途径的抑制降低了细胞膜上的EGFR水平,从而影响EGFR/AKT途径的信号转导。因此,靶向EGFR/AKT和甲羟戊酸途径增强了TMZ在GBM细胞和动物模型中的抗肿瘤作用。结论:我们的研究结果不仅揭示了EGFR激活的GBM的代谢重编程机制,而且为临床GBM管理提供了一种组合治疗策略。
{"title":"Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma","authors":"Xiaoteng Cui,&nbsp;Jixing Zhao,&nbsp;Guanzhang Li,&nbsp;Chao Yang,&nbsp;Shixue Yang,&nbsp;Qi Zhan,&nbsp;Junhu Zhou,&nbsp;Yunfei Wang,&nbsp;Menglin Xiao,&nbsp;Biao Hong,&nbsp;Kaikai Yi,&nbsp;Fei Tong,&nbsp;Yanli Tan,&nbsp;Hu Wang,&nbsp;Qixue Wang,&nbsp;Tao Jiang,&nbsp;Chuan Fang,&nbsp;Chunsheng Kang","doi":"10.1002/cac2.12502","DOIUrl":"10.1002/cac2.12502","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Metabolism reprogramming plays a vital role in glioblastoma (GBM) progression and recurrence by producing enough energy for highly proliferating tumor cells. In addition, metabolic reprogramming is crucial for tumor growth and immune-escape mechanisms. Epidermal growth factor receptor (<i>EGFR</i>) amplification and <i>EGFR-vIII</i> mutation are often detected in GBM cells, contributing to the malignant behavior. This study aimed to investigate the functional role of the EGFR pathway on fatty acid metabolism remodeling and energy generation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Clinical GBM specimens were selected for single-cell RNA sequencing and untargeted metabolomics analysis. A metabolism-associated RTK-fatty acid-gene signature was constructed and verified. MK-2206 and MK-803 were utilized to block the RTK pathway and mevalonate pathway induced abnormal metabolism. Energy metabolism in GBM with activated EGFR pathway was monitored. The antitumor effect of Osimertinib and Atorvastatin assisted by temozolomide (TMZ) was analyzed by an intracranial tumor model in vivo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>GBM with high EGFR expression had characteristics of lipid remodeling and maintaining high cholesterol levels, supported by the single-cell RNA sequencing and metabolomics of clinical GBM samples. Inhibition of the EGFR/AKT and mevalonate pathways could remodel energy metabolism by repressing the tricarboxylic acid cycle and modulating ATP production. Mechanistically, the EGFR/AKT pathway upregulated the expressions of acyl-CoA synthetase short-chain family member 3 (ACSS3), acyl-CoA synthetase long-chain family member 3 (ACSL3), and long-chain fatty acid elongation-related gene ELOVL fatty acid elongase 2 (ELOVL2) in an NF-κB-dependent manner. Moreover, inhibition of the mevalonate pathway reduced the EGFR level on the cell membranes, thereby affecting the signal transduction of the EGFR/AKT pathway. Therefore, targeting the EGFR/AKT and mevalonate pathways enhanced the antitumor effect of TMZ in GBM cells and animal models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings not only uncovered the mechanism of metabolic reprogramming in EGFR-activated GBM but also provided a combinatorial therapeutic strategy for clinical GBM management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":null,"pages":null},"PeriodicalIF":16.2,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12502","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71420969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Communications
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1